Caris Life Sciences Adds NCI-Designated UCSF Cancer Center to Precision Oncology Alliance
Caris Life Sciences added the UCSF Helen Diller Family Comprehensive Cancer Center, an NCI-designated institution, to its global Precision Oncology Alliance. The network now leverages Caris’ AI-driven platform and a multimodal database with matched molecular and clinical outcomes from hundreds of thousands of cancer patients to accelerate biomarker-driven trials.
1. UCSF Joins Precision Oncology Alliance
On April 17, 2026, Caris Life Sciences expanded its Precision Oncology Alliance by adding the UCSF Helen Diller Family Comprehensive Cancer Center, an NCI-designated institution renowned for cancer research and patient care.
2. Enhanced AI-Driven Platform and Database Scale
Members now leverage Caris’ AI-driven machine learning platform and a multimodal clinico-genomic database containing matched molecular and clinical outcomes from hundreds of thousands of cancer patients, with tens of billions of data points per patient, to inform biomarker-driven research.
3. Implications for Clinical Trial Collaborations
The inclusion of UCSF enhances access to advanced molecular insights and expands participation in biomarker-directed trials sponsored by biopharma partners, potentially accelerating therapeutic discovery and patient enrollment processes.
4. Network Expansion and Strategic Outlook
The alliance now comprises leading cancer centers, academic institutions, and healthcare systems, positioning Caris to further scale its precision oncology initiatives and strengthen its role in personalized cancer care.